376 results on '"A. Rivas-Delgado"'
Search Results
2. P1282: DISEASE-SPECIFIC U1 SPLICEOSOMAL RNA MUTATIONS IN MATURE B-CELL NEOPLASMS
3. P1277: MUTATIONAL LANDSCAPE AND COPY NUMBER ALTERATIONS IN TESTICULAR LARGE B-CELL LYMPHOMA
4. PB2088: IMMUNE PROFILE OF PATIENTS WITH FOLLICULAR LYMPHOMA ASSESSED BY FLOW CYTOMETRY IN PERIPHERAL BLOOD: CHARACTERISTICS AT DIAGNOSIS AND AT RELAPSE OF THE DISEASE
5. Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
6. Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
7. The landscape of T-cell engagers for the treatment of follicular lymphoma
8. Testicular large B‐cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL
9. Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience
10. Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
11. Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center
12. Unraveling the genetics of transformed splenic marginal zone lymphoma
13. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
14. The landscape of T-cell engagers for the treatment of follicular lymphoma.
15. Testicular large B‐cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL.
16. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma
17. Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma
18. High serum levels of IL-2R, IL-6, and TNF-α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era
19. Impact of Tocilizumab on CAR-T Cells Outcome and Toxicity: Results from a Large B Cell Lymphoma Cohort
20. Digital Droplet PCR Based Monitoring of CAR-T Cell Expansion in Lymphoma Patients: Impact on Treatment Outcome
21. IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms
22. The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome
23. A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma
24. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue
25. Serum monoclonal component in chronic lymphocytic leukemia: baseline correlations and prognostic impact
26. Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma
27. Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma
28. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma
29. IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms
30. Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience
31. Prognostic impact of <scp>MYD88</scp> and <scp>CXCR4</scp> mutations assessed by droplet digital polymerase chain reaction in <scp>IgM</scp> monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia
32. A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma.
33. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors
34. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors.
35. Supplementary tables from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study
36. Data from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study
37. Supplementary tables from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study
38. Supplemental Material from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study
39. Unraveling the genetics of transformed splenic marginal zone lymphoma
40. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors
41. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
42. Intravascular Large B-Cell Lymphoma Genomic Profile Is Characterized by Alterations in Genes Regulating NF-κB and Immune Checkpoints
43. Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstrom macroglobulinaemia
44. Intravascular Large B-Cell Lymphoma Genomic Profile Is Characterized by Alterations in Genes Regulating NF-κB and Immune Checkpoints
45. Prognostic impact ofMYD88andCXCR4mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia
46. Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia
47. The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status
48. Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia
49. NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma
50. Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.